Please assess the completion status of the following clinical trial:

Trial Title: Functional Neuroimaging of Alcoholism Vulnerability (PIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Biological father with a history of Alcoholism~* A least 1 other first- or second-degree relative with a history of Alcoholism.~Exclusion Criteria:~* Cannot be an only child~* A diagnosis of DSM-IV-TR Axis I psychotic disorders screened with the Mini International Neuropsychiatric Interview (MINI), done in the BARCS study (with the exception of Alcohol Abuse)~* Report of psychotic disorder in a 1º relative~* Prenatal exposure to alcohol (mother reported to drink 3 or more drinks on an occasion or more than 3 times per month during pregnancy~* Not speaking English fluently or being a non-native English speaker, or being educated in a primary language other than English \>grade 1~* Mental retardation (Full Scale IQ\<70)~* Traumatic brain injury with loss of consciousness \> 30 minutes or concussion in last 30 days~* Presence or history of any medical/neurologic illness that may affect brain physiology (e.g., epilepsy, Multiple Sclerosis), including focal brain lesion seen on structural MRI (all structural scans are read by a licensed radiologist)~* Current pregnancy (all females will be tested with urine screens on the day of MRI)~* Any positive alcohol screen will result in exclusion~* Inability to comprehend the consent form appropriately~* Other specific fMRI exclusions include metal devices, clips or fragments in body (orbital x-ray performed if needed)~* Female participants under 125 pounds will be excluded from participating due to the strength and side effects in this segment of the population.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Family history positive, Memantine first, then placebo (Type: EXPERIMENTAL): Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
- Family history positive, placebo first, then Memantine (Type: PLACEBO_COMPARATOR): Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
- Family history negative, Memantine first, then placebo (Type: EXPERIMENTAL): Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
- Family history negative, placebo first, then Memantine (Type: PLACEBO_COMPARATOR): Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete